Springer Resistance to Ibritumomab in Lymphoma: 18 (Resistance to Targeted Anti-Cancer Therapeutics, 18)

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab. From the Back Cover This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab. About the Author Makoto Hosono, MD, PhD, is a Professor of Radiology and Nuclear Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Japan, and serves as a member of Committee 3, International Commission on Radiological Protection.  Jean-François Chatal, MD, PhD, is an Emeritus Professor of Nuclear Medicine at the University of Nantes, France. He is one of the international leaders who developed radioimmunotherapy, that is, therapy using radiolabeled anti-tumor antibodies. He created and headed an INSERM  research laboratory and also initiated the installation of a cyclotron institute termed ARRONAX for the production of novel radionuclides for nuclear medicine.